GlassScriptPhysician profile
Leann Silhan
NPI 1952436172
$1,634.67
in general payments reported to CMS, 2019-2025
21 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,000 · 2021: $17.88 · 2022: $150 · 2023: $139 · 2024: $197 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,000.00 | 2020 | |
| Abbvie INC. | $91.99 | 2021-2025 | |
| Cleerly, INC. | $57.27 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Exact Sciences Corporation | $55.80 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $38.65 | 2022-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $36.63 | 2023-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2024-2025 | Ofev |
| Pfizer INC. | $35.27 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $32.32 | 2024 | Contrave, Onzetra Xsail |
| Antares Pharma, INC. | $31.89 | 2024 | Xyosted |
| Genentech USA, INC. | $31.51 | 2022 | |
| Merck Sharp & Dohme LLC | $23.60 | 2023 | |
| Amarin Pharma, INC. | $23.49 | 2022 | |
| Perspectum Diagnostics LTD | $20.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.70 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.72 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $17.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.32 | 2022 | |
| Echosens North America, INC. | $17.00 | 2024 | Fibroscan |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2024 | Xifaxan |
| Halozyme INC | $12.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leann Silhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.